Obesity involves hormones, metabolism, sleep, medications, stress, and genetics, often at the same time. A patient who walks four miles a week and still cannot move the number is not failing. They are usually dealing with something a physician needs to measure. Our evaluation looks at thyroid function, metabolic markers, current prescriptions that may contribute to weight gain, and related conditions, then builds a treatment plan from what the results actually show.
Families around Medlock Park and Druid Hills High School often raise a second concern: what their own health means for their kids. We treat adults, but we talk openly about how a parent's treatment tends to change what the household eats and how it moves. That ripple effect is real, and it is one of the more durable reasons patients from this area stay with a program.
Treatment may include medication, nutritional guidance, and management of related conditions, and the combination differs by patient. Nothing here is guaranteed, and we do not make outcome promises. What we can say is that we have worked with metro Atlanta patients since 2010 from one office at 5009 Roswell Road NE, Suite 201, reachable from North Druid Hills by way of I-85 and GA-400. Call (404) 341-4819 to talk with our team.
About Obesity Treatment
Obesity is a chronic medical condition, not a character flaw or a willpower problem. Excess adipose tissue changes how the body regulates hunger, satiety, insulin, blood pressure, inflammation, and energy expenditure, and those changes persist long after a diet ends. That is why most people who lose weight through effort alone regain it: the body actively defends its previous weight. Treating obesity as the metabolic disease it is means using medical tools, ongoing physician oversight, and a plan built for years rather than weeks.
Medicine has moved quickly here. A 2025 international commission proposed diagnosing obesity by organ and tissue function rather than by body mass index alone, separating people who carry excess weight without current illness from those whose health is already affected. In 2026 the American College of Physicians placed the GLP-1 medications semaglutide and tirzepatide as first-line drug therapy for adults with a BMI of 30 or higher, and for adults with a BMI of 27 or higher who also have a condition such as type 2 diabetes, high blood pressure, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Guidance now also discourages requiring patients to fail repeated diet attempts before medication is considered.
Atlanta Medical Institute has treated obesity as a physician-directed medical condition since 2010. Care is directed by Dr. Elbridge Bills, Dr. Jeff Semel, and Dr. Leslye Pace from the practice's single office on Roswell Road in Atlanta, and patients travel in from across the metro area. Treatment starts with an evaluation, not a prescription: your physician looks at your history, your weight-related conditions, your medications, and relevant laboratory work before deciding whether medication is appropriate for you and, if so, which one. No clinic can promise a specific amount of weight loss, and any program that does is selling rather than treating.
What medical obesity treatment involves
Obesity treatment at AMI begins with a physician visit that establishes what is actually driving weight gain and what it has already affected. Weight and body measurements are part of that picture, but so are blood pressure, metabolic and thyroid labs where indicated, sleep symptoms, joint pain, prior weight history, and the full list of medications you take, since several common drugs promote weight gain and sometimes can be substituted.
From there your physician builds a plan. For many patients that includes an FDA-approved anti-obesity medication alongside nutrition and activity changes. The approved options include the GLP-1 and dual-agonist injectables semaglutide and tirzepatide, an oral 25 mg semaglutide tablet approved in late 2025, liraglutide, and older oral agents such as phentermine, phentermine with topiramate, naltrexone with bupropion, and orlistat. Some of these suit a patient with reflux or migraine or hypertension better than others, which is the point of a physician choosing rather than a website.
Medication is a tool inside a program, not the whole program. Protein intake, resistance training to protect lean tissue, sleep, and management of the conditions that travel with obesity all affect how well treatment works and how durable the result is.
- Physician evaluation of weight history, weight-related conditions, and current medications
- Laboratory work as clinically indicated, including metabolic and thyroid studies
- Discussion of every appropriate FDA-approved medication option, not one product
- A nutrition and activity plan built around protecting muscle while losing fat
- Scheduled follow-up visits to adjust dosing and monitor response
- Coordination with your primary care physician or specialists when your care overlaps
Who is a candidate
Current guidance supports pharmacologic treatment for adults with a BMI of 30 or greater, and for adults with a BMI of 27 or greater who also carry at least one weight-related condition such as type 2 diabetes, prediabetes, high blood pressure, high cholesterol, fatty liver disease, obstructive sleep apnea, or established cardiovascular disease. BMI is a starting point rather than a verdict, and your physician will weigh waist measurement, body composition, and actual organ effects alongside it.
Candidacy is a medical decision made at your visit. Some patients are not appropriate for GLP-1 therapy: the labels for semaglutide and tirzepatide carry a boxed warning against use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and these medications are not used in pregnancy or while trying to conceive. A history of pancreatitis, significant gastroparesis, active gallbladder disease, severe kidney impairment, or certain eating disorders calls for careful review and sometimes a different approach entirely.
Patients who are not candidates for one medication are often candidates for another. That is one reason the evaluation matters more than the drug name people arrive asking for.
- BMI of 30 or higher, or 27 or higher with a weight-related medical condition
- Weight that is affecting blood pressure, blood sugar, lipids, sleep, joints, or liver
- Prior weight loss that did not hold, which is the expected pattern rather than a failure
- Willingness to attend follow-up visits, since dosing is adjusted over time
- No contraindication identified during your medical evaluation
What to expect over the first year
Injectable and oral GLP-1 medications are started at a low dose and increased gradually. The slow escalation is deliberate: it gives the digestive system time to adapt and reduces nausea, and it also means meaningful change is measured over months rather than the first few weeks. Your physician determines the pace, and it is normal for one patient to hold at a dose while another moves up.
Results vary widely from person to person, and published trial averages are not a forecast for any individual. What your physician tracks is broader than the scale: blood pressure, blood sugar and A1c, lipids, waist measurement, energy, joint symptoms, sleep quality, and how well you are eating. Several obesity medications now carry indications for specific related conditions, including tirzepatide for moderate to severe obstructive sleep apnea in adults with obesity and semaglutide for cardiovascular risk reduction in adults with established cardiovascular disease and for certain stages of metabolic dysfunction-associated steatohepatitis.
Obesity behaves like other chronic conditions in one important way. A 2026 systematic review found that, on average, people regained roughly 60 percent of the weight lost on GLP-1 therapy within a year of stopping it. That is not a reason to avoid treatment; it is a reason to plan the long-term phase with your physician rather than assume a course of medication is a one-time event.
Safety, monitoring, and honest limits
The common side effects of GLP-1 medications are gastrointestinal: nausea, vomiting, diarrhea, constipation, reflux. Most are dose-related and ease with time or a slower titration. Less common but more serious concerns include pancreatitis, gallbladder problems, kidney injury from dehydration during prolonged vomiting, and increased heart rate. Anyone on these medications who is scheduled for surgery or a procedure under sedation should tell the anesthesia team, because delayed stomach emptying affects preoperative planning.
Rapid weight loss also costs lean tissue. A meaningful share of the weight lost on any effective obesity treatment can come from muscle rather than fat, which is why adequate protein and resistance training are part of the plan rather than optional extras. Your physician monitors this alongside your labs at follow-up visits.
One point AMI states plainly: compounded semaglutide and tirzepatide are not FDA-approved products. The FDA removed both drugs from its shortage list in 2024 and 2025, and in April 2026 proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances large outsourcing facilities may compound. Compounded versions, including salt forms sold online, have not been evaluated by the FDA for safety or effectiveness. Discuss with your physician what you are being prescribed and why.
- Scheduled follow-up visits while dosing is adjusted, then at intervals your physician sets
- Laboratory monitoring as clinically indicated for your history and medications
- Prompt reporting of severe abdominal pain, persistent vomiting, or signs of dehydration
- Telling any surgeon or anesthesiologist that you are taking a GLP-1 medication
- Attention to protein intake and resistance training to protect lean mass
- A clear conversation about what is FDA-approved and what is not
Getting Here from North Druid Hills
Patients typically take North Druid Hills Road (SR 42) west to I-85, then head north to GA-400 and exit toward Lenox Road or Wieuca Road, crossing over to Roswell Road NE just south of Chastain Park; drivers coming from the Toco Hills side often use LaVista Road or Briarcliff Road to reach I-85 instead.
5009 Roswell Road NE, Suite 201
Atlanta, GA 30342
We see patients from across North Druid Hills and nearby areas including Toco Hills, Briarcliff, Medlock Park, North Druid Woods, Executive Park.
Obesity Treatment in North Druid Hills — Frequently Asked Questions
Is obesity treatment different from a weight loss program?
Medical obesity treatment addresses obesity as a chronic condition, including related conditions and any metabolic or hormonal factors found on evaluation. Your physician determines which treatments, including medications where appropriate, fit your situation.
I already exercise regularly. Is there anything left to try?
Often yes. Activity is only one input. Thyroid function, insulin resistance, sleep, and certain prescription medications can all affect weight, and those require testing rather than more effort. An evaluation is where you find out.
Do you treat patients who live outside Atlanta city limits?
Yes. North Druid Hills is unincorporated DeKalb County, and many of our patients travel in from there and from surrounding communities. Our single office is in Atlanta on Roswell Road NE, open Monday through Thursday 9 to 6 and Friday 9 to 4.
Is obesity really a disease, or just a weight problem?
Major medical bodies treat obesity as a chronic disease. Excess adipose tissue alters hormonal signaling, appetite regulation, insulin sensitivity, blood pressure, and inflammation, and those changes persist and push weight back up after dieting. A 2025 international commission went further and proposed diagnosing obesity by its effect on organ and tissue function rather than by BMI alone. Treating it medically reflects that biology.
Do I have to fail at dieting before AMI will consider medication?
No. Current guidance, including the American College of Physicians' 2026 recommendation, does not require patients to try and fail lifestyle changes before starting pharmacotherapy. Your physician makes the decision based on your BMI, your weight-related conditions, your medical history, and your goals. Nutrition and activity remain part of the plan either way, but they are not a hurdle you must clear first.
How do you decide which medication is right for me?
Your physician considers your BMI, the weight-related conditions you already have, your other medications, your history with prior treatments, your tolerance for injections versus pills, and any contraindications. Semaglutide and tirzepatide are first-line for many adults, but they are not right for everyone, and older oral medications are a better fit for some patients. Eligibility for any of them is determined by medical evaluation, not by an online questionnaire.
What happens if I stop the medication?
Weight regain is common after stopping. A 2026 systematic review found that people regained about 60 percent of the weight they had lost within a year of discontinuing GLP-1 therapy, with regain tending to plateau after that. Obesity is a chronic condition, so your physician will talk with you about maintenance dosing, tapering, or other long-term strategies rather than treating a course of medication as a finish line.
Are compounded GLP-1 medications the same as Wegovy or Zepbound?
No. Compounded semaglutide and tirzepatide are not FDA-approved, and the agency has warned about unapproved salt forms sold online. The FDA removed both medications from its shortage list in 2024 and 2025 and in April 2026 proposed permanently excluding them from the bulk substances outsourcing facilities may use. Ask any provider directly whether what they are prescribing is an FDA-approved product.
Will treating obesity help the other conditions I have?
It often helps, though no one can promise a particular result for an individual. Sustained weight reduction is associated with improvement in blood pressure, blood sugar, lipids, sleep apnea severity, and joint symptoms for many patients. Some medications now carry specific indications: tirzepatide for moderate to severe obstructive sleep apnea in adults with obesity, and semaglutide for cardiovascular risk reduction in adults with established cardiovascular disease and for certain stages of fatty liver disease with fibrosis. Your physician will tell you what is realistic in your case.
Want the full clinical detail? Read about our Obesity Treatment program.